Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into
an agreement with MultiGEN Diagnostics Inc., of San Diego, California,
for exclusive rights to market MultiGEN’s unique diagnostic tests based
on multiplex DNA sequencing, in the state of New York. In addition, Enzo
has been granted marketing rights for other non-exclusive territories in
United States.
“These particular tests utilize
true state of the art technology and offer physicians serving women
highly accurate and convenient options for improved patient service.”
Enzo will validate and seek approval of an Antenatal Infectious Disease
panel as well as a thrombophilia panel pursuant to New York, New Jersey
and CLIA [Clinical Laboratory Improvement Act] requirements, in addition
to marketing, and securing third party reimbursement for the test. Terms
were not disclosed. Enzo said that subject to regulatory and
reimbursement approval, among others, it hopes to make the test
available in the second half of 2010.
The tests bolster Enzo’s already strong portfolio of women’s health
diagnostics. The antenatal panel allows for simultaneous identification
of certain bacterial viral or fungal pathogens in a single convenient
specimen. Additionally, the thrombophilia panel detects multiple
mutations that can diagnose genetic predisposition to blood clotting.